You are here

  • Home
  • Archive
  • Volume 7, Issue 4
  • Growth rate was greater with fluticasone propionate than with beclomethasone dipropionate in children with chronic asthma

Article Text

Article menu
Download PDFPDF
Therapeutics
Growth rate was greater with fluticasone propionate than with beclomethasone dipropionate in children with chronic asthma

https://doi.org/10.1136/ebm.7.4.114

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2001) Arch Pediatr Adolesc Med 155, 1248; de Benedictis FM, Teper A, Green RJ, et al, for the International Study Group.. Effects of 2 inhaled corticosteroids on growth. Results of a randomized controlled trial.. Nov;. :. –54.
    OpenUrlPubMedWeb of Science

    
 
 QUESTION: In children with chronic asthma, what are the effects of fluticasone propionate compared with those of beclomethasone dipropionate on growth rates?

    Design

    Randomised (allocation concealed*), blinded (unclear),* controlled trial with 12 months of follow up.

    Setting

    32 centres in 7 countries: The Netherlands, Hungary, Italy, Poland, Argentina, Chile, and South Africa.

    Patients

    343 children who were 4 to 11 years of age (mean age 8y, 72% boys); had a sexual maturity rating of Tanner stage 1; required treatment with fluticasone propionate, 100 to 200 μg/day, or beclomethasone dipropionate or budesonide, 200 to 500 μg/day, for ≥ 8 weeks before study entry at a constant dosage for ≥ 4 weeks before the run-in period; had a mean morning peak expiratory flow rate (PEFR) during the last 7 days of the run-in period of ≤ 85% of their maximum achievable response after using a metered dose inhaler containing albuterol sulphate, 400 μg; and had an asthma symptom score ≥ …

    View Full Text

    Footnotes

    • Source of funding: GlaxoSmithKline, Uxbridge, UK.

    • For correspondence: Dr F M de Benedictis, Clinica Pediatrica, Policlinico Monteluce, Perugia, Italy. debened{at}unipg.it.

    • ↵* See glossary.